ライフサイエンスコーパス: pericardial effusion

1 ation or PR depression, and new or worsening pericardial effusion).

2 lar right atrial mass and moderate to severe pericardial effusion.

3 rdial rub, electrocardiographic changes, and pericardial effusion.

4 ve leaflets, and interatrial septum and mild pericardial effusion.

5 chest were obtained and indicated increasing pericardial effusion.

6 olated without steam pop, impedance rise, or pericardial effusion.

7 anized because of hypotension from a serious pericardial effusion.

8 icular dilation and dysfunction, and a large pericardial effusion.

9 more likely to have periaortic hematoma and pericardial effusion.

10 ed satisfactory device position and excluded pericardial effusion.

11 in cardiac enzyme elevation, perforation, or pericardial effusion.

12 tions of its treatment are a common cause of pericardial effusion.

13 leviate high-volume and low-volume (<200 mL) pericardial effusions.

14 sia, pleural effusions, chylothoraces and/or pericardial effusions.

15 e events included hemorrhage and pleural and pericardial effusions.

16 l myocardial edema and fibrosis and frequent pericardial effusions.

17 patients with rupture or tamponade, 75% had pericardial effusions.

18 ications were device embolization (1.9%) and pericardial effusion (1.9%), with no cases of periproced

19 %], and 10 [0.4%], respectively; P>0.05) and pericardial effusion (11 [0.4%], 11 [0.8%], and 12 [0.5%

20 ronary syndromes (ACS) (1C), the presence of pericardial effusion (1C), cardiac tamponade (1B), valvu

21 , p < 0.001) along with higher incidences of pericardial effusion (20%, 0%, 0%, p < 0.001) and gastro

22 sion (12%), reticular infiltration (4%), and pericardial effusion (4%).

23 ications included: generalized edema (5.5%), pericardial effusion (5.5%), facial edema (2.2%), and up

24 re echocardiography domains (adequate views, pericardial effusion, acute cor pulmonale, left ventricu

25 int: symptomatic cardiac events (symptomatic pericardial effusion, acute coronary syndrome, pericardi

26 The poor survival among cancer patients with pericardial effusion and abnormal fluid cytology may hav

27 hemodynamic and echocardiographic variables, pericardial effusion and an enlarged right atrium remain

28 gainst fog1 resulted in embryos with a large pericardial effusion and an unlooped heart tube.

29 t pain and epigastric pain was found to have pericardial effusion and pneumopericardium on computed i

30 higher risk of complications, predominantly pericardial effusion and procedural stroke related to ai

31 s reviewed as well as current treatments for pericardial effusions and constrictive pericarditis.

32 Pericardial effusions and myocardial fibrosis were 3 and

33 c AD but is more frequently complicated with pericardial effusions and periaortic hematoma.

34 not otherwise specified within 30 days, one pericardial effusion) and one in consolidation phase (es

35 embryonic day 10.5 and have thin ventricles, pericardial effusion, and a reduction in ventricular myo

36 endpoint for safety included major bleeding, pericardial effusion, and device embolisation.

37 sia, patent ductus arteriosus, cardiomegaly, pericardial effusion, and lymphoedema.

38 e rates of death, stroke, systemic embolism, pericardial effusion, and major bleeding were 5.8%, 1.9%

39 d growth retardation, marked bradycardia and pericardial effusions, and generalized edema, signs that

40 primary tool for diagnosing and quantifying pericardial effusions, and in the context of the clinica

41 b: acute renal failure; pleural effusion and pericardial effusion; and brain metastasis.

42 or bleeding, 9 had major bleeding, and 1 had pericardial effusion but no tamponade.

43 There were no pericardial effusions, but serious procedure/device-rela

44 Pericardial effusions can be insidious, variable in pres

45 A retrospective review of pericardial effusion coincident with sirolimus therapy w

46 kg every 4 weeks plus tremelimumab 1 mg/kg), pericardial effusion (durvalumab 20 mg/kg every 4 weeks

47 The adverse reaction of pericardial effusion has been added to product labeling.

48 greater than 10 mm Hg among patients with a pericardial effusion helps distinguish those with cardia

49 , 1.777-6.584; P<0.001), and the presence of pericardial effusion (HR, 1.38; 95% confidence interval,

50 occurred in 43 infants, cardiac arrest, and pericardial effusion in 17 infants, and noninfective thr

51 nd spontaneous reports) contained reports of pericardial effusion in 56 sirolimus-treated patients, 3

52 n unusual case of massive pseudolymphomatous pericardial effusion in a cardiac transplant recipient.

53 We report here a rare case of pericardial effusion in a pediatric patient secondary to

54 Malignancy is the most common cause of pericardial effusion in a tertiary care center.

55 y revealed esophagopericardial fistulas with pericardial effusion in all patients, while contrast lea

56 tive model: p = 0.0161) were associated with pericardial effusion in females relative to healthy fema

57 ary-vein stenosis developed in two patients, pericardial effusion in one, and pulmonary edema in anot

58 nitial echocardiographic evaluation revealed pericardial effusions in 13 group A versus 4 group B fet

59 us greater than 10 mm Hg in a patient with a pericardial effusion increases the likelihood of tampona

60 Cancer-related pericardial effusion is associated with adverse outcomes

61 Although benign pericardial effusion is frequently seen in the post-card

62 The differential diagnosis of pericardial effusion is reviewed as well as current trea

63 is accompanied by hypotension and cyanosis, pericardial effusion, low voltage on the electrocardiogr

64 Malignant pericardial effusion may require emergency pericardiocen

65 = 1), left ventricular dysfunction (n = 1), pericardial effusion (n = 1), secondary bacterial or fun

66 pericarditis post-operatively (n = 2), late pericardial effusion (n = 1), unexplained sudden death (

67 ds), including pericardial tamponade (n=19), pericardial effusion (n=5), atrial perforation (n=3), J

68 f mortality included age, ejection fraction, pericardial effusion, N-terminal pro-B-type natriuretic

69 Significant pericardial effusion occurred in 16 patients (10.4%).

70 A significantly higher rate of pericardial effusion occurred with sirolimus versus azat

71 Although most of the pericardial effusions occurred in cardiac transplantatio

72 onfidence interval, 1.4-6.2; P<0.001), and a pericardial effusion (odds ratio, 2.5; 95% confidence in

73 cted carbon monoxide diffusing capacity, and pericardial effusion on echocardiogram all predicted mor

74 edural stroke without increasing the risk of pericardial effusion or other bleeding complications.

75 No animal had pericardial effusion or tamponade.

76 rdiomyopathy, who also exhibit polycythemia, pericardial effusion, or goiter should be evaluated for

77 Pericardial effusion (p = 0.003) and indexed right atria

78 Pericardial effusion (p = 0.017), indexed right atrial a

79 Pericardial effusion (PE) is common in cancer patients,

80 Four patients had bleeding complications (pericardial effusion, pericardial hematoma, hemoperitone

81 distress, along with weight gain, pleural or pericardial effusions, peripheral edema, thromboembolic

82 n, myocardial performance index, presence of pericardial effusion, pulmonary vascular resistance, car

83 The natural history of pericardial effusion remains largely unknown.

84 Pericardial effusions requiring surgical repair decrease

85 Pericardial effusions resolved and reappeared in both gr

86 Pericardial effusion, right atrial enlargement and septa

87 These data suggest that pericardial effusion should be considered in the differe

88 uded bleeding- and procedure-related events (pericardial effusion, stroke, device embolization).

89 Knockdown of emp2 in zebrafish resulted in pericardial effusion, supporting the pathogenic role of

90 IPAH, after controlling for the presence of pericardial effusion; there was no significant change in

91 rformed safely in the absence of preexisting pericardial effusion to provide a novel route for cardia

92 ment of left ventricular function, ischemia, pericardial effusion, valvular disease, heart donor stat

93 requiring immunosuppressant withdrawal, the pericardial effusion was a benign EBV-negative T cell pr

94 Cancer-related pericardial effusion was associated with decreased survi

95 A pericardial effusion was evident on fetal ultrasound in

96 ity and only 1 hemodynamically insignificant pericardial effusion was observed at follow-up.

97 ion, severe valvular insufficiency and large pericardial effusion) was 99.0% (95% confidence interval

98 Cases of pericardial effusion were also observed in the sirolimus

99 Patients with cancer-related pericardial effusion were more likely to require repeat

100 Hypertension and pericardial effusion were not associated with decreased

101 Pericardial effusions were common.

102 Pericardial effusions were excluded by serial echocardio

103 were observed in 29% of patients; pleural or pericardial effusions were observed in 1% (none were sev

104 h a history of chronic aortic dissection and pericardial effusion who was admitted to a teaching hosp

105 heart disease in HIV-1-infected patients are pericardial effusion with cardiac tamponade, high-grade

106 eeding, and 2 patients developed symptomatic pericardial effusion with need for pericardiocentesis 1

107 oped minor bleeding, and 1 patient developed pericardial effusion with no tamponade.

108 rt an unusual case of spontaneous Ureaplasma pericardial effusion with tamponade associated with pneu

109 s with preserved LVEF in 2, and an important pericardial effusion with tamponade in another.

110 Infectious pericardial effusion with tamponade is an uncommon but l

111 ere was a significantly higher rate of large pericardial effusions with LBN compared with MPN (8.1% v

112 The rate of serious pericardial effusion within 7 days of implantation, whic